Alnylam Pharmaceuticals
ALNY
499 hedge funds and large institutions have $22.4B invested in Alnylam Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 167 increasing their positions, 160 reducing their positions, and 44 closing their positions.
118% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 44
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
10% more funds holding
Funds holding: 453 → 499 (+46)
4% more repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 160
0.87% less ownership
Funds ownership: 94.23% → 93.36% (-0.87%)
9% less capital inflows, than outflows
Capital inflows: $988M | Capital outflows: $1.09B
17% less call options, than puts
Call options by funds: $267M | Put options by funds: $321M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$144M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$133M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$83.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$37.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$204M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$165M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$98.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$75.1M |
| 5 |
Morgan Stanley
New York
|
-$68.6M |
ALNY Hedge Fund Activity: Q4 2023 in Review
499 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2023, worth a combined $22.4B — up 7.5% from $20.9B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new ALNY positions and 44 closed out — a net gain of 52 holders — while 167 added to existing stakes and 160 trimmed.
The largest buyer was Norges Bank, adding an estimated $144M. The largest seller was Baillie Gifford & Co, cutting an estimated $204M.
- 499 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2023, up from 453 in Q3 2023.
- Funds reported $22.4B of Alnylam Pharmaceuticals stock for Q4 2023, up 7.5% quarter-over-quarter.
- 96 funds opened new Alnylam Pharmaceuticals positions in Q4 2023 and 44 closed out, a net change of +52 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2023 was Norges Bank, an estimated $144M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2023 was Baillie Gifford & Co, an estimated $204M sold.
Based on aggregated 13F filings for Q4 2023.